Key result
Direct oral anticoagulants showed no statistically significant difference in embolic and hemorrhagic complication rates compared to vitamin K antagonists in patients with deep vein thrombosis.
Why the study?
The study was conducted to evaluate the complication rates, including embolic and hemorrhagic events, in deep venous thrombosis patients receiving direct oral anticoagulant therapy versus vitamin K antagonist therapy.
Does direct oral anticoagulant therapy compared to vitamin K antagonist therapy reduce embolic and hemorrhagic complications in patients with deep venous thrombosis?
Observational (n=62)
No
Does direct oral anticoagulant therapy compared to vitamin K antagonist therapy reduce embolic and hemorrhagic complications in patients with deep venous thrombosis?
Absolute Event Rate: 23.5% vs 32.1%
p-value: p=0.637
In a small retrospective cohort of DVT patients, there was no significant difference in embolic or hemorrhagic complication rates between those treated with DOACs versus VKAs.
No difference in this small retrospective DVT cohort should not change practice; leaves open DOAC-VKA equivalence for complications.
The objective of the current study is to evaluate the complication rates (embolic and hemorrhagic events) in deep venous thrombosis (DVT) patients on different types of oral anticoagulation therapy (OAC): direct oral anticoagulant therapy and vitamin K antagonist therapy. Methods: A number of 62 DVT patients were included and divided in two groups, depending on the type of oral anticoagulation therapy administered. The first group was composed of patients treated with direct oral anticoagulant treatment (Dabigatran, Rivaroxaban) and the second group was composed of patients treated with vitamin K antagonist (Acenocumarol). General data, including BMI and comorbidities were noted. Embolic and hemorrhagic events were noticed. Results : in the first group of patients (DOAC therapy), a number of 34 patients were included (14 of them with BMI higher than 25 kg/m2 and 14 with concomitant atrial fibrillation), while the second group comprised of 28 patients treated with VKA (21 of them with a high BMI and only 3 of them with atrial fibrillation). After a mean period of 36 months of anticoagulant therapy, complications were present in 17 patients, hematuria (8 episodes) and pulmonary embolism (4 cases) were the most frequent, with no difference regarding the treatment applied. Conclusion: No statistically significant difference was encountered regarding embolic and hemorrhagic event rates in our deep vein thrombosis patients.
No takes yet. Share an insight, caveat, or question.
Cozlea et al. (2019) conducted an observational in Deep venous thrombosis (n=62). Direct oral anticoagulants (Dabigatran, Rivaroxaban) vs. Vitamin K antagonist (Acenocoumarol) was evaluated on Complication rates (embolic and hemorrhagic events) (p=0.637). Direct oral anticoagulants showed no statistically significant difference in embolic and hemorrhagic complication rates compared to vitamin K antagonists in patients with deep vein thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: